Robinhood, MicroStrategy And Other Big Losers From Wednesday
U.S. stocks closed lower on Wednesday, with the Dow Jones dipping more than 600 points. Here is the list of some big stocks recording losses in the previous session.
Mirum Presents New Data From LIVMARLI Phase 3 PFIC Study And ALGS Infant Study In Late-Breaker Presentations At The Liver Meeting Of AASLD; Phase 3 MARCH Study Meets Primary Endpoint
- Phase 3 MARCH study meets primary endpoint and demonstrates statistical significance across key endpoints in all PFIC types. Receives Best of Liver Meeting
CANbridge Announces Encouraging Development In Maralixibat/LIVMARLI In Rare Liver Disease/ Congratulates Partner Mirum On Topline Phase 3 Data In Progressive Familial Intrahepatic Cholestasis
Congratulates Mirum on Positive Topline Phase 3 Data in progressive familial intrahepatic cholestasis (PFIC)
CANbridge holds exclusive Greater China license to maralixibat (CAN108) in liver diseases, China trial
Raymond James Maintains Strong Buy on Mirum Pharmaceuticals, Raises Price Target to $88
Raymond James analyst Steven Seedhouse maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Strong Buy and raises the price target from $75 to $88.
HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $68
HC Wainwright & Co. analyst Ed Arce maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $63 to $68.
Mirum Pharmaceuticals Announces CHMP Opinion For LIVMARL Oral Solution For Cholestatic Pruritus In Patients With Alagille Syndrome Two Months Of Age And Older
- CHMP opinion based on pivotal ICONIC study with more than five years of data demonstrating durable and clinically meaningful improvements in cholestatic pruritus and serum bile acids for patients with Alagille syndrome
‘It Is Too Sizzling For Me’: Why Jim Cramer Isn’t Buying This ‘Red Hot’ Group Of Stocks
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Kelly Services, Inc. (NASDAQ: KELYA) is a "very well-run company. Right now, with people just feeling it’s easy to get a job, you don’t need them. That’s why that stock has been such a dog.
Looking Into Mirum Pharmaceuticals’s Return On Capital Employed
According to Benzinga Pro data, during Q2, Mirum Pharmaceuticals (NASDAQ:MIRM) posted sales of $17.48 million. Earnings were up 26.45%, but Mirum Pharmaceuticals still reported an overall loss of $26.92 million.
Here’s Why Mirum Pharmaceuticals Stock Is Getting Hammered
Mirum Pharmaceuticals Inc (NASDAQ: MIRM) shares are trading lower by 13.46% to $23.79 Wednesday afternoon after the company priced its common stock offering of 3.478 million shares at $23 per share.
What Happened?